Shots:
- The companies collaborated to evaluate Treos’ PolyPEPI1018 (Polypeptide cancer immunotherapy) + Roche’s atezolizumab (PD-L1-inhibitor) in P-I/II trial in patients with late-stage MSS mCRC which is expected to initiate in Q4’21
- Treos has completed a P- I/II OBERTO 101 study for PolyPEPI1018 as 1L maintenance setting in patients with MSS mCRC that demonstrates the therapy was safe & well-tolerated and induced T cell responses against multiple tumor targets
- Following the non-exclusive collaboration, Treos will conduct the study & maintains full ownership of PolyPEPI1018 whereas Roche to provide all required doses of atezolizumab
Click here to read full press release/ article | Ref: Globe Newswire | Image: PharmaLive
The post Roche Enters into a Clinical Collaboration with Treos Bio for PolyPEPI1018 + atezolizumab in P-I/II Trial to Treat Late Stage Microsatellite Stable Metastatic Colorectal Cancer first appeared on PharmaShots.
